Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
NCT06398639
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Polygenic Risk Score
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 to 69 years
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- Adam S. Kibel, MD
- Last updated on ClinicalTrials.gov
- November 10, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Brigham and Women's Hospital · Boston, MA
- Massachusetts General Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.